summary: In this randomised double-blind placebo-controlled phase II trial, the safety and tolerability of natalizumab when added to glatiramer acetate, was investigated in 110 patients with relapsing remitting MS. The authors found that after the 6-month treatment period the combination treatment was safe. Moreover, significant differences were observed between the two groups in terms of MRI parameters favouring the combination treatment.

authors: Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, Lublin F, Khan O, Bormann NM, Yang M, Panzara MA, Sandrock AW; For the GLANCE investigators

source: Neurology. 2009 Mar 3;72(9):806-812

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: